Acelyrin, Inc.
NASDAQ Global SelectTotal Valuation
Acelyrin, Inc. carries a market capitalization of 229.17M, placing it among publicly traded companies globally. Its enterprise value stands at -157.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 229.17M |
| Enterprise Value | -157.89M |
Share Statistics
Acelyrin, Inc. currently has 100.91M shares outstanding.
| Shares Outstanding | 100.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.31 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | -0.87 |
| P/OCF Ratio | -0.86 |
Financial Position
Acelyrin, Inc. maintains a current ratio of 18.43, meaning it holds 18.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 18.43 |
| Quick Ratio | 18.33 |
| Debt / Equity | 1.47 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -47.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Acelyrin, Inc.'s stock has declined approximately -42.96482% over the past 52 weeks. The 50-day moving average sits at 2.40, while the 200-day moving average is 3.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | -42.96482% |
| 50-Day Moving Average | 2.40 |
| 200-Day Moving Average | 3.55 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -281.46M, while operating income came in at -281.94M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -281.94M |
| Pretax Income | -268.52M |
| Net Income | -268.52M |
| EBITDA | -281.46M |
| EBIT | -281.94M |
| Earnings Per Share (EPS) | -2.69 |
Balance Sheet
Acelyrin, Inc. holds 410.59M in cash and equivalents against 5.97M in total debt, resulting in a net debt position of -58.27M. Total book value stands at -792.21M, with working capital of 406.19M providing operational flexibility.
| Cash & Cash Equivalents | 410.59M |
| Total Debt | 5.97M |
| Net Debt | -58.27M |
| Equity (Book Value) | -792.21M |
| Book Value Per Share | -7.93 |
| Working Capital | 406.19M |
Cash Flow
Acelyrin, Inc. produced -285.58M in operating cash flow over the past twelve months. After subtracting -1.19M in capital expenditures, free cash flow totaled -286.77M - equivalent to -2.87 per share.
| Operating Cash Flow | -285.58M |
| Capital Expenditures | -1.19M |
| Free Cash Flow | -286.77M |
| FCF Per Share | -2.87 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.05 |
| FCF Yield | -115.26 |
Scores
Acelyrin, Inc. posts an Altman Z-Score of 1.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.50 |